News By Company | Aurinia Pharmaceuticals Inc. News on T-Net

1 - 10 of 37 Results

Victoria-based Aurinia Announces U.S. FDA Approval for its LUPKYNIS Therapy for Adult Patients with Active Lupus Nephritis - Stock Soars 26%

Victoria, BC, January 26, 2021--Aurinia Announces U.S. FDA Approval for its LUPKYNIS™ (voclosporin) Therapy for Adult Patients with Active Lupus Nephritis - Stock Soars 26%

Snapshot | Profile | News | Follow

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Victoria, BC, December 31, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) and Lonza Ltd. (SIX: LONN) announced they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonza's existing small molecule API facility in Visp, Switzerland.

Snapshot | Profile | News | Follow

Aurinia Receives Upfront Payment of U.S. $50 Million for Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co.

Victoria, BC, December 29, 2020--Aurinia Receives Upfront Payment of U.S. $50 Million for Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosp

Snapshot | Profile | News | Follow

Victoria, BC-based Aurinia Pharmaceuticals Announces Outcome of AUDREY Clinical Trial in Dry Eye Syndrome

Victoria, BC, November 10, 2020--Aurinia Pharmaceuticals Inc.(Nasdaq: AUPH / TSX:AUP), a late-stage clinical biopharmaceutical company, announced topline data from the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES).

Snapshot | Profile | News | Follow

Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome

Victoria, BC, September 30, 2020--Aurinia Pharmaceuticals Inc.(NASDAQ: AUPH / TSX:AUP), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple autoimmune conditions, announced that the last patient study visit has occurred in the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES).

Snapshot | Profile | News | Follow

Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights

Victoria, BC, August 19, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company) reported financial results for the second quarter ended June 30, 2020 and provided an update on recent operational highlights. Cash, cash equivalents and short term investments totaled approximately $442.06 million at July 31, 2020.

Snapshot | Profile | News | Follow

Victoria-based BioPharm Company Aurinia Announces U.S. FDA Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin

Victoria, BC, August 4, 2020--Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for voclosporin, as a potential treatment for lupus nephritis (LN), a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus (SLE).

Snapshot | Profile | News | Follow

Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Solution for the Treatment of Dry Eye Syndrome

Victoria, BC, June 23, 2020--Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced it has completed enrollment for the Phase 2/3 AUDREY™ clinical trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES), a chronic disease estimated to affect more than 16 million people in the United States.

Snapshot | Profile | News | Follow

Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020

Victoria, BC, June 12, 2020--Aurinia Pharmaceuticals (Nasdaq:AUPH / TSX:AUP), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that additional safety data from the completed AURORA pivotal trial of voclosporin were shared at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 2020 Virtual Congress.

Snapshot | Profile | News | Follow

Aurinia Reports Strong Cash Position, Q1-2020 Financial Results and Recent Operational Highlights

Victoria, BC, May 14, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) reported financial results for the first quarter ended March 31, 2020 and provided an update on recent operational highlights. Cash and cash equivalents totaled approximately $286 million at March 31, 2020 US.

Snapshot | Profile | News | Follow